Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2011 - 2026)

Vanda Pharmaceuticals has reported Total Non-Current Liabilities for 15 years, with the latest figure at $142.6 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 28.18% year-over-year to $142.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $142.6 million (up 28.18% YoY) and the FY2025 annual result came in at $152.2 million, up 40.86% from the prior year.
• Total Non-Current Liabilities fell to $142.6 million in Q1 2026 per VNDA's latest filing, from $152.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $152.2 million in Q4 2025 and troughed at $92.3 million in Q3 2023.
• A 5-year average of $108.6 million and a median of $100.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities retreated 9.08% in 2023, then surged 40.86% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $100.2 million in 2022, then declined by 5.53% to $94.7 million in 2023, then climbed by 14.12% to $108.1 million in 2024, then surged by 40.86% to $152.2 million in 2025, then declined by 6.3% to $142.6 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $142.6 million, $152.2 million, and $124.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.